Curis, Inc. (NASDAQ:CRIS)
Shares of Curis, Inc. (NASDAQ:CRIS) are down 17.5% after the biotechnology company reported a (-$15.5) million, or (-$0.11) per share, loss on $2.4 million in revenue for Q3 2017. The company’s results were below analyst expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of (-$0.09) cents per share. For the same period last year, Curis reported a net loss of (-$28.3) million, or (-$0.21) per share.
Curis, Inc. (NASDAQ:CRIS) is a biotechnology company that develops and commercializes drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis also collaborates with Aurigene in the areas of immuno-oncology and precision oncology. Curis is also in collaboration with biotechnology giant Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
CRIS Stock Performance
Shares of Curis, Inc. (NASDAQ:CRIS) hit new 52-week lows, $1.23, after the earnings announcement was released. The 52-week high was established back in November of 2016. However, shares have taken a beating since then and lost over 40% of their value. Year-to-date, CRIS stock performs even worse – down over 50%.
All four investments firms that follow Curis, Inc. (NASDAQ:CRIS) rate CRIS shares as a “Strong Buy” and have a consensus price target of $5.50. This is noteworthy as sales have been in decline for the past five years. In 2012, the company posted sales of $17 million. That figure shrank every year and for 2016 sales were posted at just $7.5 million. On top of the poor sales performance, CRIS shares have had negative earnings for the past five years with the two largest losses coming in 2015 (-$0.48) and 2016 (-$0.46).
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $CRIS and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.